These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 27629849)

  • 41. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
    Parise CA; Bauer KR; Brown MM; Caggiano V
    Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between NF-κB, ER, PR, Her2/neu, Ki67, p53 expression in human breast cancer.
    Shapochka DO; Zaletok SP; Gnidyuk MI
    Exp Oncol; 2012 Dec; 34(4):358-63. PubMed ID: 23302996
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [HIF-1alpha expression and relationship involving tumor cell proliferation and angiogenesis in human breast carcinoma].
    Hao LS; Wang G; Qian K; Luo T; Li XJ; Wu XT
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jan; 38(1):60-3. PubMed ID: 17294729
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer.
    Bauer K; Parise C; Caggiano V
    BMC Cancer; 2010 May; 10():228. PubMed ID: 20492696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinicopathological characteristics of metaplastic breast cancer - analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types.
    Budzik MP; Patera J; Sobol M; Czerw AI; Deptała A; Badowska-Kozakiewicz AM
    Breast; 2019 Feb; 43():135-141. PubMed ID: 30553188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
    Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
    Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low expression of Beclin 1 and elevated expression of HIF-1α refine distant metastasis risk and predict poor prognosis of ER-positive, HER2-negative breast cancer.
    Dong M; Wan XB; Yuan ZY; Wei L; Fan XJ; Wang TT; Lv YC; Li X; Chen ZH; Chen J; Lin Q; Wen JY; Ma XK; Liu Q; Wu XY
    Med Oncol; 2013 Mar; 30(1):355. PubMed ID: 23408367
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas.
    Okada K; Osaki M; Araki K; Ishiguro K; Ito H; Ohgi S
    Anticancer Res; 2005; 25(4):3003-9. PubMed ID: 16080559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas.
    Giatromanolaki A; Sivridis E; Fiska A; Koukourakis MI
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):78-82. PubMed ID: 16540735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distribution and prognosis of molecular breast cancer subtypes defined by immunohistochemical biomarkers in a Spanish population-based study.
    Puig-Vives M; Sánchez MJ; Sánchez-Cantalejo J; Torrella-Ramos A; Martos C; Ardanaz E; Chirlaque MD; Perucha J; Díaz JM; Mateos A; Machón M; Marcos-Gragera R
    Gynecol Oncol; 2013 Sep; 130(3):609-14. PubMed ID: 23747837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
    Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield S; Bersiga A; Allevi G; Milani M; Aguggini S; Gandolfi V; Dogliotti L; Bottini A; Harris AL; Fox SB
    Clin Cancer Res; 2006 Aug; 12(15):4562-8. PubMed ID: 16899602
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythropoietin and erythropoietin receptor expression in vestibular schwannoma: potential role in tumor progression.
    Diensthuber M; Ilner T; Rodt T; Samii M; Brandis A; Lenarz T; Stöver T
    Otol Neurotol; 2007 Jun; 28(4):559-65. PubMed ID: 17429338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymphatic vascularization in primary breast cancer: HER2 overexpressing tumors contain more lymphatics than steroid receptor positive, triple-positive and triple negative breast carcinomas.
    Popovska S; Ivanov I
    Turk Patoloji Derg; 2014; 30(2):124-32. PubMed ID: 24782302
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinicopathological characteristics of oestrogen receptor negative, progesterone receptor positive breast cancers: re-evaluating subsets within this group.
    Ahmed SS; Thike AA; Zhang K; Lim JC; Tan PH
    J Clin Pathol; 2017 Apr; 70(4):320-326. PubMed ID: 27612503
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Age interacts with the expression of steroid and HER-2 receptors in operable invasive breast cancer.
    Neven P; Van Calster B; Van den Bempt I; Van Huffel S; Van Belle V; Hendrickx W; Decock J; Wildiers H; Paridaens R; Amant F; Leunen K; Berteloot P; Timmerman D; Van Limbergen E; Weltens C; Van den Bogaert W; Smeets A; Vergote I; Christiaens MR; Drijkoningen M
    Breast Cancer Res Treat; 2008 Jul; 110(1):153-9. PubMed ID: 17687649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
    Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
    Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.
    Kazi AA; Gilani RA; Schech AJ; Chumsri S; Sabnis G; Shah P; Goloubeva O; Kronsberg S; Brodie AH
    Breast Cancer Res; 2014 Jan; 16(1):R15. PubMed ID: 24472707
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Could the Breast Prognostic Biomarker Status Change During Disease Progression? An Immunohistochemical Comparison between Primary Tumors and Synchronous Nodal Metastasis.
    El Nemr Esmail RS; El Farouk Abdel-Salam LO; Abd El Ellah MM
    Asian Pac J Cancer Prev; 2015; 16(10):4317-21. PubMed ID: 26028092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
    J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.